Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
Published: April 01, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.
Published: March 31, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the ordinary shares of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive.
Read More
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
ROSEN, A LEADING NATIONAL FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
Published: March 30, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.
Read More
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025 ? Affected uniQure N.V.
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
Published: March 27, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.
Read More
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).
Read More
QURE INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: March 27, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UniQure N.V.
Read More
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data
Published: March 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 25, 2026 (GLOBE NEWSWIRE) -- - National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
QURE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: March 25, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 25, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.
Read More
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
Published: March 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
Read More
ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
Published: March 24, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.
Read More
QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
Published: March 24, 2026 by: PRNewsWire
Sentiment: Neutral
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
Published: March 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
Read More
QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: March 20, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 20, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UniQure N.V.
Read More
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class Action Lawsuit — The Gross Law Firm
Published: March 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).
Read More
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V.
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
Read More
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Published: March 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).
Read More
QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options
Read More
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
Published: March 18, 2026 by: PRNewsWire
Sentiment: Neutral
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.
Read More
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Published: March 09, 2026 by: Market Watch
Sentiment: Positive
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Read More
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Published: March 09, 2026 by: Market Watch
Sentiment: Positive
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Read More
QURE Stock Crashes 32% in a Week: Here's What You Should Know
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Negative
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
Read More
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Read More
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, March 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure's business, operations, and prospects, including allegations that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; and (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License …
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Matthew Craig Kapusta
- Employees 209